Article Text

other Versions

PDF
Randomised controlled trial
Nebulised hypertonic saline does not reduce hospital length of stay in acute bronchiolitis
  1. Todd A Florin
  1. Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
  1. Correspondence to: Dr Todd A Florin, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, 3333 Burnet Avenue, ML 2008, Cincinnati, OH 45229, USA; Todd.Florin{at}cchmc.org

Statistics from Altmetric.com

Commentary on: OpenUrlAbstract/FREE Full Text

Context

Acute bronchiolitis is the most frequent lower respiratory infection in infancy, yet no therapy has shown consistent benefit.1 Although initially promising, there is now conflicting evidence regarding the efficacy of nebulised 3% hypertonic saline (HS). In 2013, a Cochrane meta-analysis concluded that HS may significantly reduce the hospital length of stay among infants hospitalised with mild-to-moderate bronchiolitis and also improve clinical severity scores.2 Other studies suggest that HS has no effect on length of stay.3 ,4

Methods

This study was a multicentre, parallel-group, open-label randomised trial comparing 4 mL of nebulised HS administered every 6 h to standard supportive care in infants aged <1 year hospitalised at 1 of 10 hospitals in the UK. …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.